CBS 2019
CBSMD教育中心
中 文

急性冠脉综合征

Abstract

Recommended Article

Hospital Readmission After Perioperative Acute Myocardial Infarction Associated With Noncardiac Surgery Wearable Cardioverter-Defibrillator after Myocardial Infarction Restenosis, Stent Thrombosis, and Bleeding Complications - Navigating Between Scylla and Charybdis How Will the Transition to hs-cTn Affect the Diagnosis of Type 1 and 2 MI? Relationship between therapeutic effects on infarct size in acute myocardial infarction and therapeutic effects on 1-year outcomes: A patient-level analysis of randomized clinical trials Impact of door-to-balloon time on long-term mortality in high- and low-risk patients with ST-elevation myocardial infarction Complete Revascularization During Primary Percutaneous Coronary Intervention Reduces Death and Myocardial Infarction in Patients With Multivessel Disease-Meta-Analysis and Meta-Regression of Randomized Trials 4-Step Protocol for Disparities in STEMI Care and Outcomes in Women

Original Research2014 Oct 10;3(5):e001250.

JOURNAL:J Am Heart Assoc. Article Link

Trends in early aspirin use among patients with acute myocardial infarction in China, 2001-2011: the China PEACE-Retrospective AMI study

Gao Y, Masoudi FA, China PEACE Collaborative Group. Keywords: acute myocardial infarction; aspirin; quality of care

ABSTRACT


BACKGROUND - Aspirin is an effective, safe, and inexpensive early treatment of acute myocardial infarction (AMI) with few barriers to administration, even in countries with limited healthcare resources. However, the rates and recent trends of aspirin use for the early treatment of AMI in China are unknown.


METHODS AND RESULTS - Using data from the China Patient-centered Evaluative Assessment of Cardiac Events Retrospective Study of Acute Myocardial Infarction (China PEACE-Retrospective AMI Study), we identified a cohort of 14 041 patients with AMI eligible for early aspirin therapy. Early use of aspirin for AMI increased over time (78.4% in 2001, 86.5% in 2006, and 90.0% in 2011). However, about 15% of hospitals had a rate of use of <80% in 2011. Treatment was less likely in patients who were older, presented with cardiogenic shock at admission, presented without chest discomfort, had a final diagnosis of non-ST-segment elevation acute myocardial infarction, or did not receive reperfusion therapy. Hospitalization in rural regions was also associated with aspirin underuse.



CONCLUSIONS - Despite improvements in early use of aspirin for AMI in China, there remains marked variation in practice and opportunities for improvement that are concentrated in some hospitals and patient groups.



CLINICAL TRIAL REGISTRATION URL - ClinicalTrials.gov Unique identifier: NCT01624883.


© 2014 The Authors. Published on behalf of the American Heart Association, Inc., by Wiley Blackwell.